Chronic treatment with a carbon monoxide releasing molecule reverses dietary induced obesity in mice

Carbon monoxide potently prevents ischemia-induced high-mobility group box 1 translocation and release and protects against lethal renal ischemia–reperfusion injury

(2014) Yongle Ruan et al.   KIDNEY INTERNATIONAL

Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994

(2013) Mariana Lazo et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Carbon monoxide-releasing molecules reverse leptin resistance induced by endoplasmic reticulum stress

(2013) Min Zheng et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals

(2013) Howard C. Masuoka et al.   Annals of the New York Academy of Sciences

Inflammation triggers high mobility group box 1 (HMGB1) secretion in adipose tissue, a potential link to obesity

(2013) Manoj Kumar Gunasekaran et al.   CYTOKINE

Chronic carbon monoxide treatment attenuates development of obesity and remodels adipocytes in mice fed a high-fat diet

(2013) P A Hosick et al.   INTERNATIONAL JOURNAL OF OBESITY

Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21

(2013) Terry D. Hinds et al.   Obesity

Soluble HMGB1 Is a Novel Adipokine Stimulating IL-6 Secretion through RAGE Receptor in SW872 Preadipocyte Cell Line: Contribution to Chronic Inflammation in Fat Tissue

(2013) Brice Nativel et al.   PLoS One

Carbon Monoxide Improves Cardiac Function and Mitochondrial Population Quality in a Mouse Model of Metabolic Syndrome

(2012) Steve Lancel et al.   PLoS One

A carbon monoxide-releasing molecule (CORM-3) uncouples mitochondrial respiration and modulates the production of reactive oxygen species

(2011) Luisa Lo Iacono et al.   FREE RADICAL BIOLOGY AND MEDICINE

Chronic HO-1 induction with cobalt protoporphyrin (CoPP) treatment increases oxygen consumption, activity, heat production and lowers body weight in obese melanocortin-4 receptor-deficient mice

(2011) E Csongradi et al.   INTERNATIONAL JOURNAL OF OBESITY

Adipocyte Heme Oxygenase-1 Induction Attenuates Metabolic Syndrome in Both Male and Female Obese Mice

(2010) Angela Burgess et al.   HYPERTENSION

The therapeutic potential of carbon monoxide

(2010) Roberto Motterlini et al.   NATURE REVIEWS DRUG DISCOVERY

Up-Regulating the Hemeoxygenase System Enhances Insulin Sensitivity and Improves Glucose Metabolism in Insulin-Resistant Diabetes in Goto-Kakizaki Rats

(2009) Joseph Fomusi Ndisang et al.   ENDOCRINOLOGY

Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats

(2009) Angelique Nicolai et al.   HYPERTENSION

Carbon Monoxide Rescues Mice from Lethal Sepsis by Supporting Mitochondrial Energetic Metabolism and Activating Mitochondrial Biogenesis

(2009) S. Lancel et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Heme-Oxygenase-1 Induction and Carbon Monoxide-Releasing Molecule Inhibit Lipopolysaccharide (LPS)-Induced High-Mobility Group Box 1 Release in Vitro and Improve Survival of Mice in LPS- and Cecal Ligation and Puncture-Induced Sepsis Model in Vivo

(2009) K. Tsoyi et al.   MOLECULAR PHARMACOLOGY

Treatment of Obese Diabetic Mice With a Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance

(2008) M. Li et al.   DIABETES

L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice

(2008) Stephen J. Peterson et al.   JOURNAL OF LIPID RESEARCH

Pharmacological and Clinical Aspects of Heme Oxygenase

(2008) N. G. Abraham et al.   PHARMACOLOGICAL REVIEWS